Integral Health Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Integral Health Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-150,000	Closed	-$3.25M	–	80
2025 Q2	$3.25M	Hold	150,000	–	–	0.3%	66
2025 Q1	$3.64M	Sell	150,000 -150,000	-50%	-$3.38M	0.39%	63
2024 Q4	$6.26M	Sell	300,000 -100,000	-25%	-$2.15M	0.53%	56
2024 Q3	$7.95M	Buy	400,000 +125,000	+45%	+$2.32M	0.89%	31
2024 Q2	$4.26M	Buy	+275,000	New	+$4.28M	0.4%	57

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integral Health Asset Management's CPRX Position: Q3 2025 in Review

Integral Health Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2025, closing a stake of 150,000 shares — an estimated $3.25M sold.

Integral Health Asset Management first reported a position in CPRX in Q2 2024 and held it in 5 quarters. The position peaked at $7.95M in Q3 2024. 360 funds tracked by Wall St. Rank hold CPRX as of Q3 2025.

Integral Health Asset Management reported no remaining Catalyst Pharmaceutical position as of Q3 2025 after selling out during the quarter.
Integral Health Asset Management sold 150,000 Catalyst Pharmaceutical shares in Q3 2025, an estimated $3.25M.
Integral Health Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2024 and held it in 5 quarters.
Integral Health Asset Management's Catalyst Pharmaceutical position peaked at $7.95M in Q3 2024.
360 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2025.

Based on Integral Health Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.